Ignite Creation Date:
2025-12-24 @ 7:52 PM
Ignite Modification Date:
2025-12-28 @ 5:25 AM
Study NCT ID:
NCT02767804
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-10-14
First Post:
2016-04-30
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Sponsor:
Xcovery Holdings, Inc.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2016-06
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-31
Completion Date Type:
ESTIMATED
First Submit Date:
2016-04-30
First Submit QC Date:
None
Study First Post Date:
2016-05-10
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-10-08
Last Update Post Date:
2025-10-14
Last Update Post Date Type:
ESTIMATED